SillaJen

Busan, South Korea Founded: 2006 • Age: 20 yrs
Oncolytic immunotherapeutics are developed for cancer treatment.

About SillaJen

SillaJen is a company based in Busan (South Korea) founded in 2006.. SillaJen has raised $12 million across 1 funding round from investors including Medivate Partners. The company has 45 employees as of December 31, 2024. SillaJen has completed 1 acquisition, including Jennerex Biotherapeutics. SillaJen offers products and services including Marketing Services, Education Programs, and Consulting Services. SillaJen operates in a competitive market with competitors including Replimune, Candel Therapeutics, Adlai Nortye, Transgene and Nouscom, among others.

  • Headquarter Busan, South Korea
  • Employees 45 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sillajen, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $2.66 M (USD)
    -0.33
    as on Dec 31, 2024
  • Net Profit
    $-17.99 M (USD)
    -30.22
    as on Dec 31, 2024
  • EBITDA
    $-17.47 M (USD)
    -26.75
    as on Dec 31, 2024
  • Total Equity Funding
    $12 M (USD)

    in 1 rounds

  • Latest Funding Round
    $12 M (USD), Private Equity Round

    Mar 21, 2016

  • Investors
  • Employee Count
    45

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of SillaJen

SillaJen is a publicly listed company on the KRX with ticker symbol 215600 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 215600 . Sector: Health technology · South Korea

Products & Services of SillaJen

SillaJen offers a comprehensive portfolio of products and services, including Marketing Services, Education Programs, and Consulting Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Provides strategies for salon promotion and online visibility

Offers courses on beauty business management and marketing

Delivers advice on salon operations and client analysis

People of SillaJen
Headcount 50-200
Employee Profiles 5
Employee Profiles
People
Su Jin Lee M.D.
Medical Director
People
Sangkeun(SK) Park
Head Of Research And Development, CEO of Sillajen US
People
Hyunmin Lee
Clinical Operations / CPM

Unlock access to complete

Funding Insights of SillaJen

SillaJen has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Private Equity Round round of $12 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Private Equity Round — $12.0M
  • First Round

    (21 Mar 2016)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2016 Amount Private Equity Round - SillaJen Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SillaJen

SillaJen has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Medivate Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SillaJen

SillaJen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Jennerex Biotherapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Oncolytic viruses for cancer treatment are developed by the company.
2003
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - SillaJen

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sillajen Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SillaJen

SillaJen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Replimune, Candel Therapeutics, Adlai Nortye, Transgene and Nouscom, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of oncolytic immunotherapies
domain founded_year HQ Location
Viral immunotherapies are developed for cancer treatment.
domain founded_year HQ Location
Immune oncolytic therapies for cancer are developed.
domain founded_year HQ Location
Therapeutic vaccines for cancer and infectious diseases are developed.
domain founded_year HQ Location
Viral-vector-based vaccines for cancer treatment are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sillajen

Frequently Asked Questions about SillaJen

When was SillaJen founded?

SillaJen was founded in 2006 and raised its 1st funding round 10 years after it was founded.

Where is SillaJen located?

SillaJen is headquartered in Busan, South Korea.

Is SillaJen a funded company?

SillaJen is a funded company, having raised a total of $12M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $12M, raised on Mar 21, 2016.

How many employees does SillaJen have?

As of Dec 31, 2024, the latest employee count at SillaJen is 45.

What is the annual revenue of SillaJen?

Annual revenue of SillaJen is $2.66M as on Dec 31, 2024.

What does SillaJen do?

SillaJen was founded in 2006 and is based in Busan, South Korea. Operations focus on the biotechnology sector, where oncolytic immunotherapeutics are developed to treat various cancers. The lead product candidate, Pexa-Vec, an engineered oncolytic virus, targets advanced primary liver cancer and is in mid-stage development for kidney cancer and other solid tumors. Research emphasizes viral therapies to enhance immune responses against tumors.

Who are the top competitors of SillaJen?

SillaJen's top competitors include Replimune, Vyriad and Candel Therapeutics.

What products or services does SillaJen offer?

SillaJen offers Marketing Services, Education Programs, and Consulting Services.

Is SillaJen publicly traded?

Yes, SillaJen is publicly traded on KRX under the ticker symbol 215600.

How many acquisitions has SillaJen made?

SillaJen has made 1 acquisition, including Jennerex Biotherapeutics.

Who are SillaJen's investors?

SillaJen has 1 investor. Key investors include Medivate Partners.

What is SillaJen's ticker symbol?

The ticker symbol of SillaJen is 215600 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available